TransCode Therapeutics Inc. RNAZ
1.69
0.04
2.42%
as of 25 Sep
- Market cap
- $27.9M
- P/E
- 0.0×
Follow RNAZ
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
1.97 | 3.11 | 6.29 | 1.60 |
+8 more quarters Free account |
Net Debt/EBITDA |
1.24 | 0.72 | 1.11 | 0.62 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 0.26 | 0.54 | 0.84 | |
Capex/Depreciation |
0.00 | 0.00 | (0.15) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.93 | 0.89 | 0.86 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | |
Free Cash Flow per Share |
(5.64) | (5.43) | (11.81) | (4.90) | |
Cash per Share |
8.76 | 14.00 | 25.83 | 3.40 | |
Shareholders Equity per Share |
(28.93) | 1.36 | 14.99 | 1.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(28.93) | 1.36 | 14.99 | 1.71 | |
Free Cash Flow |
(5.40) | (4.98) | (8.15) | (4.08) | |
Working Capital |
5.24 | 11.37 | 18.49 | 1.78 | |
Capital Expenditures |
— | — | (0.01) | — | |
Net Current Asset Value |
(168.06) | (139.16) | (130.08) | 0.95 | |
| Other line items | |||||
Quick Ratio |
1.55 | 2.39 | 5.37 | 1.02 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(5.64) | (5.43) | (11.81) | (4.90) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Average Receivables |
0.09 | 0.16 | 0.48 | 0.28 | |
Average Payables |
3.12 | 3.90 | 3.10 | 2.55 | |
Average Assets |
79.64 | 85.18 | 84.85 | 4.58 | |
Average Common Equity |
(10.77) | 5.77 | 4.16 | 1.54 | |
Capex to Sales |
— | — | 0.00 | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates